Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 219

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 219
---
 1,613 1,164 SPN-8201,111 6,668 8,073 20,010 SPN-8174,872 2,815 11,889 5,835 Qelbree3,168 5,621 9,805 11,552 ZURZUVAE1,385 — 1,385 — Early-stage programs and other expenses5,173 4,343 11,865 12,516 Total external development program expenses16,061 19,518 44,630 51,077 Internal employee-related expenses13,305 9,518 33,778 29,072 Total research and development expenses29,366 29,036 78,408 80,149 Other segment items(c)9,211 20,820 48,689 54,991 Net earnings (loss)$(45,117)$38,497 $(34,445)$58,537 (a) Excludes Sage Acquisition related expenses which are presented in the separate line item, Acquisition-related expenses, in the table above. (b) Sage Acquisition related expenses includes primarily transaction costs incurred, post-combination employee-related expenses incurred by the Company, and share-based compensation expense for Sage incurred to accelerate the vesting of certain equity awards under the terms of the Merger Agreement.(c) Other segment items include amortization of intangible assets, contingent consideration gain or loss, net interest and other income, and income tax expense or benefit whose amounts are disclosed in the condensed consolidated statement of earnings (loss).

15. Collaboration Agreements

Navitor See Note 17, Commitments and Contingencies, for further details.ShionogiThe Company is party to a collaboration and license agreement with Shionogi whereby Shionogi is responsible for all clinical development and regulatory filings for zuranolone in MDD and other indications in Japan, the Republic of Korea (South Korea), and Taiwan (together, the Shionogi Territory) and would be responsible for commercialization of zuranolone in the Shionogi Territory, if zuranolone is successfully developed and obtains marketing approval in any of the countries within the 

31

Shionogi Territory. Shionogi was required to make an upfront payment to the Company of $90.0 million, and the Company is eligible to receive additional payments of up to $470.0 million if certain regulatory and commercial milestones